Selected Relevant Publications from the Sagene Team:


Azzaro A.J., Blob L.F., et al.,Evaluation of the Potential for Pharmacodynamic and Pharmacokinetic Drug Interactions Between Selegiline Transdermal System and Two Sympathomimetic Agents (Pseudoephedrine and Phenylpropanolamine) in Healthy Volunteers. J Clin Pharmacol. 2007 Aug;47(8): 978-990.

Azzaro A.J., et al.,Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-1267.

Thomas T., Nadackal G.T., and Thomas P.Inhibition of LDL oxidation by theneuroprotective drug l-deprenyl. Neurol. Res. 24: 169-173, 2002.

Barrett J.S., Hochadel T.J., et al.,Pharmacokinetics and Safety of a Selegiline Transdermal System Relative to Single-Dose Oral Administration in the Elderly. Am J Ther. 1996 Oct;3(10): 688-698.

Barrett J.S., Hochadel T.J., et al.,Pharmacokinetics and Safety of a Selegiline Transdermal System Relative to Single-Dose Oral Administration in the Elderly. Am J Ther. 1996 Oct;3(10): 688-698.

Mawhinney M., Cole D., Azzaro A.J.Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol. 2003 Jan;55(1): 27-34.

Thomas T., McLendon C., and Thomas G.L-Deprenyl: nitric oxide production and dilation of cerebral blood vessels. NeuroReport, 9 (11): 2595-2600, 1998.

Selegiline Safety

Azzaro A.J., Blob L.F., et al.,Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects. J Clin Pharmacol. 2006 Aug;46(8): 933-44.

Azzaro A.J., Blob L.F., et al.,Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. CNS Spectr. 2007 Jan;12(1): 25-34.

Azzaro A.J., et al.,Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications. J Clin Pharmacol. 2007 Feb;47(2): 146-58.

VanDenBerg C.M., Blob L.F., Kemper E.M., Azzaro A.J.Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol. 2003 Jun;43(6): 604-9.

Erectile Dysfunction

Carson C.C.Central Nervous System–Acting Agents and the Treatment of Erectile and Sexual Dysfunction. Curr Urol Rep. 2007 Nov;8(6): 472-6.

Carson C.C.Commentary on apomorphine versus sildenafil for erectile dysfunction. J Urol. 2008 May;179(5 Suppl): S92-4.

Carson C.C.Cardiac Safety in Clinical Trials of Phosphodiesterase 5 Inhibitors. Am J Cardiol. 2005 Dec 26;96(12B): 37M-41M. Epub 2005 Dec 5.

Pain & Inflammation

Thomas T., Nadackal G., Thomas K.Aspirin and non-steroidal antiinflammatory drugs prevent amyloid-beta aggregation. NeuroReport. 12: 3263-3267, 2001.

Thomas T., Nadackal G., Thomas K.Aspirin and diabetes: Inhibition of amylin aggregation by nonsteroidal antiinflammatory drugs. Exptl. and Clinical Endocrinology and Diabetes. 1: 1-5, 2003.

Thomas T. et al.,A comparison of anti-inflammatory activities of CEE and 17-β estradiol. Inflammation Research. 52: 452-461, 2003.

Rhodin J. and Thomas T.,et al.,In vivo cerebrovascular actions of amyloid-β peptides and the protective effect of CEE. Journal of Alzheimer’s Disease. 5: 275-286, 2003.

Vascular and Neurodegenerative Diseases

Thomas T., et al.,β-amyloid- mediated vasoactivity and vascular endothelial damage. Nature 380: 168-171, 1996.

Thomas T., Sutton E.T., Hellerman A., and Price, J.M.β-amyloid-induced coronary arteryvasoactivity and endothelial damage. J. Cardiovasc. Pharm. 30: 1-6, 1997.

Thomas T.Monoamine oxidase-B inhibitors in the treatment of Alzheimer’s disease. Neurobiol. Aging. 21: 343-348, 2000.

Thomas T. and Rhodin J.A.Vascular actions of estrogen and Alzheimer’s disease. Ann. NY Acad. Sci.. 903: 501-509, 2000.

Rhodin J., Thomas T. et al.,Animal model of Alzheimer-like vascular pathology and inflammatory reaction. Ann NY Acad. Sci. 903: 2000.

Rhodin J.A. and Thomas T.A vascular connection to Alzheimer’s disease. Microcirc. 8: 207-220, 2001.